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Sttmmtary 
Vascular permeability factor (VPF)  is a highly conserved 34-42-kD protein secreted by many 
tumor cells. Among the most potent vascular permeability-enhancing factors known, VPF is 
also a selective vascular endothelial cell mitogen, and therefore has been called vascular endothelial 
cell growth factor (VEGF). Our goal was to define the cellular sites of VPF (VEGF) synthesis 
and accumulation in tumors in vivo. Immunohistochemical  studies were performed on solid and 
asdtes guinea pig line 1 and line 10 bile duct carcinomas using antibodies directed against peptides 
synthesized to represent the NH2-terminal and internal sequences  of VPF.  These antibodies 
stained tumor cells and, uniformly and most intensely, the endothelium of immediately adjacent 
blood vessels, both preexisting and those newly induced by tumor angiogenesis. A similar pattern 
of VPF  staining was  observed in  autochthonous human lymphoma. In  situ  hybridization 
demonstrated VPF mRNA in nearly all line 10 tumor cells but not in tumor blood vessels, 
indicating that immunohistochemical  labeling of tumor vessels with antibodies to VPF peptides 
reflects uptake of VPF, not endogenous synthesis. VPF protein staining was evident in adjacent 
preexisting venules and small veins as early as 5 h after tumor transplant and plateaued at maximally 
intense levels in newly induced tumor vessels by -5  d. VPF-stained vessels were also hyper- 
permeable to macromolecules as judged by their capacity to accumulate circulating colloidal carbon. 
In contrast, vessels more than "~0.5 mm distant from tumors were not hyperpermeable and did 
not exhibit immunohistochemical staining for VPF. Vessel staining disappeared within 24-48 h 
of tumor rejection. These studies indicate that VPF is synthesized by tumor cells in vivo and 
accumulates in nearby blood vessels, its target of action. Because leaky tumor vessels initiate 
a cascade of events, which include plasma extravasation and which lead ultimately to angiogenesis 
and tumor stroma formation, VPF may have a pivotal role in promoting tumor growth. Also, 
VPF immunostaining provides a new marker for tumor blood vessels that may be exploitable 
for tumor imaging or therapy. 
V 
ascular permeability factor (VPF) is thought to be respon- 
sible for the vascular hyperpermeability and consequent 
plasma protein-rich fluid accumulation that occurs in solid 
and ascites tumors (1-3).  In addition, VPF exerts a number 
of other effects on vascular endothelial cells (EC); e.g., VPF 
increases intracelhlar caldum, stimulates inositol triphosphate 
formation, provokes yon Willebrand factor release, and stimu- 
lates tissue factor expression (4, 5). VPF is also a specific EC 
mitogen and has been alternatively called vascular endothelial 
cell growth factor (VEGF) (6-9). 
In the present study, we used in situ hybridization and 
immunohistochemistry  to define the distribution of VPF in 
tumors in vivo. Not unexpectedly, abundant VPF mRNA 
and protein were present in tumor cells. Of great interest, 
however,  staining for VPF protein was selectively concen- 
trated in tumor-associated blood vessels, the putative target 
of VPF action in angiogenesis and tumor stroma generation. 
Materials and Methods 
Animals, Tumors, and An@eptide Antibodies.  Ascites variants of 
chemically induced guinea pig line 1 and line 10 bile duct carci- 
nomas were passaged in the peritoneal cavities of inbred strain 2 
guinea pigs (1). To form solid tumors, 3  x  10  6 washed ascites 
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pigs (1). To identify leaky blood vessels, colloidal carbon was in- 
jected  intravenously  30  min  before  tumor  harvest  (10). Au- 
tochthonous  human tumors were obtained after surgery. 
The NH2-terminal 25-amino acid sequence of guinea pig VPF, 
here designated peptide 1A and expressed in single letter code, is 
APMAEGEQKPREVVKFMDVYKRSYC  (11). The 26-amino 
acid NH2 terminus of human VPF (peptide 1B) differs from that 
of guinea  pig  VPF  by  the  six  underlined  amino  acids: AP- 
MAEGGGQNHHEVVKFMDVYQRSYC  (8). These and an in- 
ternal peptide (CECILPKKDRARQEKKSVR,  peptide 6) corre- 
sponding to amino acids 102-119 of the 189-amino acid form of 
human VPF (8) were synthesized, coupled to a protein carrier, and 
used to immunize rabbits (11). 
Immunohistockemistry  and ln Situ Hybridization.  Guinea  pig tissues 
were fixed  in formalin or carbodiimide and embedded in paraffin. 
Fresh frozen sections of human tumors were fixed in acetone, lm- 
munohistochemistry was performed on 5-7/~m paraffin or frozen 
sections, using affinity-purified first antibodies to guinea pig or 
human VPF peptides and an avidin-biotin peroxidase procedure. 
Controls included substitution  of the first antibody with an un- 
related rabbit antipeptide antibody, preabsorption of first antibody 
with specific peptide, and on-the-slide competition for first anti- 
body with specific peptide. 
In situ hybridization was performed using 3sS-labeled single- 
stranded RNA probes prepared by in vitro transcription of a 204- 
bp guinea pig VPF cDNA fragment cloned in pGem3Zf(+) (12; 
B. Berse et al., manuscript submitted for publication). 
Results and Discussion 
Localization of VPF (VEGF)  in  Tumors by Immunohisto- 
chemistry and In situ Hybridization.  Initial immunohistochem- 
ical studies were performed on growing, 5-8-d solid tumors. 
The most striking finding was that the new blood vessels 
induced by both line 1 and line 10 tumors stained consis- 
tently and intensdy with antibodies to VPF peptides 1A and 
6 (Fig.  1). Vessd staining was circumferential and involved 
EC and vascular basement membranes; sometimes, adjacent 
extracellular matrix also stained weakly (Fig.  1, A  and D). 
Line 1 tumors underwent ceU-mediated immune rejection 
(3) which was accompanied by a striking and rapid (within 
24--48 h) loss of vessd staining (not shown). The rapid deple- 
tion of VPF that accompanied tumor destruction suggests 
rapid turnover of blood vessel-associated VPF.  Preliminary 
studies with antibodies to VPF peptide l_B indicate that human 
tumors also exhibit VPF  staining and in a pattern similar 
to that of guinea pig tumors (Fig.  1 G). 
In addition to the tumor microvasculature,  vessds coursing 
through immediately adjacent normal tissues  also exhibited 
specific antibody staining (Fig.  1 F). Immunoreactive vessels 
were venules and small veins within m0.5 mm of tumors; 
arterioles, capillaries,  and vessels of any type at greater dis- 
tances from tumor or in other tissues  and organs exhibited 
no staining. Consistent with these findings, antibodies to VPF 
peptide 1A also stained immediately adjacent, preexisting host 
venules and small veins as early as 5 h after tumor cell trans- 
plant. These preexisting blood vessels, as well as induced tumor 
vessels, were hyperpermeable as judged by their concentra- 
tion of circulating colloidal carbon (10). 
A minority of tumor cells stained with antibody to VPF 
peptide 1A, but nearly all stained with the antibody to pep- 
tide 6 (Fig.  1, A, B~ and/4), suggesting that VPF is abun- 
dantly present in nearly all tumor cells. The poor tumor cell 
staining with antipeptide 1A probably represents failure of 
fixation to preserve cytoplasmic VPF in a conformation ac- 
cessible  to this antibody. Using in situ hybridization (Fig. 
2), nearly all line 10 solid or ascites tumor cells reacted with 
the antisense RNA probe for guinea pig VPF mRNA; how- 
ever, tumor blood vessels were negative for VPF transcript. 
Relation of VPF (VEGF) Synthesis and Accumulation to Tumor 
Stroma Generation.  Our data clearly indicate that VPF is abun- 
dantly synthesized by tumor cells but not detectably by EC; 
therefore, the VPF identified in tumor-associated vessds reflects 
selective binding of tumor cell-secreted VPF. We did not un- 
equivocally identify the precise vascular structures to which 
tumor cell-secreted VPF bound. EC have receptors for VPF 
(4, 13, 14), and it is likely that some of the staining represents 
VPF that has bound to the EC surface or that has been sub- 
sequently internalized. However, VPF also binds to heparin 
(2),  and some of the staining may reflect binding of VPF 
to heparin-like proteoglycans present either in the vascular 
basement membrane or associated with EC. Indeed, cell sur- 
face heparin-like molecules are required for binding bFGF, 
another growth factor implicated in angiogenesis, to its high 
affinity receptor (15). 
The intense tumor vessel labeling observed with anti-VPF 
peptide antibodies was unexpected. VPF exerts its effects on 
vascular endothelium at low nM to sub-pM concentrations, 
well below those detectable by immunohistochemistry; e.g., 
staining could not be demonstrated when VPF was injected 
into normal guinea pig skin in amounts that greatly increased 
local vascular hyperpermeability. Therefore, VPF accumulates 
in tumor blood vessels in amounts much greater than those 
necessary to trigger vascular responses. Tumor vessel binding 
may provide a mechanism for retaining and concentrating 
VPF, thereby maximizing its activity locaUy while preventing 
its spread to more distal sites. 
Taken together, our data support a model of tumor stroma 
generation that is initiated by tumor cell secretion of VPF 
(1, 3). VPF acts directly on EC, initially to induce vascular 
hyperpermeability and later to maintain hyperpermeability 
and to promote endothelial cell growth, perhaps in concert 
with other growth factors such as bFGF (16). Tumor vessel 
hyperpermeability results in  extravasation and clotting of 
fibrinogen to form an extravascular fibrin gel that provides 
a favorable substrate for invasion by fibroblasts and EC (3, 10); 
together, these transform the fibrin gel into granulation tissue 
and, later, into desmoplastic scar. Fibrin gds alone can repli- 
cate this entire response without the need for tumor cells 
or exogenous growth factors (3). Thus, with its dual actions 
on EC permeability and proliferation, VPF initiates and per- 
petuates a chain of events that produces tumor stroma by 
a process analogous to normal wound healing (3). 
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line 10 (A-C, E, F, H and/) and line 
1 (D) guinea pig bile duct carcinomas 
and a human large cell lymphoma (G) 
demonstrated with antibodies directed 
against guinea pig or human VPF pep- 
tides: (A-F) peptide 1A; (G) peptide 1B; 
(H and/) peptide 6. Immunohistochem- 
ical reaction  product  appears yellow- 
brown. (,4) Overview showing minimal 
staining of line 10 tumor cells (T) with 
antibody  to  peptide  1A  but  intense 
staining  of  tumor-associated  blood 
vessels 8 d after transplant.  Focally, ad- 
jacent  stroma (s) is also stained. (B-D) 
Higher magnification  photographs il- 
lustrating  variable line  10 tumor cell 
staining (B) and intense staining of line 
10 (C) and line 1 (D) tumor vessels; (s) 
staining of adjacent stroma.  (E) New, 
ascites tumor-induced  blood vessel of 
the peritoneal wall stains intensely; at- 
tached tumor  cells  (anow)  are unstained; 
(pc) peritoneal  cavity. (F) Preexisting 
venules of normal skeletal muscle adja- 
cent to a line  10 tumor are strongly 
stained with antibody to peptide  1A. 
(G) Vessels in a human B cell lymplioma 
react strongly with antibody to peptide 
lB. (H and/) Staining of nearly all line 
10 tumor cells (/4) and a nearby venule 
(arrow in/) with antibodies to peptide 
6. As with antibodies to the VPF NH2 
terminus,  adjacent  venules and small 
veins (arrow  in/) stain intensely, but ar- 
teries (a in/) stain faintly or not at all; 
(,4)  x245; (BandD)  x405; (C)  x313; 
(E,  F,  and/-/)  x260;  (G)  x320;  (/) 
x410. 
Finally,  it should be noted that VPF immunostaining  dis- 
tinguishes tumor blood vessels from those found elsewhere 
in tumor-bearing or control animals.  This finding stands in 
contrast to the widespread distribution of bFGF in vascular 
basement membranes of normal  tissues (17).  VPF provides 
a new marker for tumor blood vessels and may offer a useful 
target  for tumor  imaging  and  therapy. 
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1277  Dvorak et al.  Brief Definitive  Report Figure 2.  Autoradiographs  representing  in situ hybridization  performed on paraflfin  sections  of solid line 10 tumors with 3sS-labeled  antisense (/1 
and B) and sense (C) RNA probes to guinea pig VPF mRNA. With antisense probes, labeling is observed over nearly all tumor cells (A) but not 
over adjacent  microvessels  (v in B). Autoradiograph  exposure times in A were selected to permit clear visualization  of cells underlying grains. With 
the corresponding sense probe (C), tumor cells are not labeled, even after lengthy exposures; (A)  xS00; (B and C)  x385. 
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